- Home
- SPCE vs ACRS Comparison
SPCE vs ACRS Comparison
Compare SPCE & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCE
- ACRS
- Stock Information
- Founded
- SPCE 2017
- ACRS 2012
- Country
- SPCE United States
- ACRS United States
- Employees
- SPCE N/A
- ACRS N/A
- Industry
- SPCE Transportation Services
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- SPCE Consumer Discretionary
- ACRS Health Care
- Exchange
- SPCE Nasdaq
- ACRS Nasdaq
- Market Cap
- SPCE 148.0M
- ACRS 165.7M
- IPO Year
- SPCE N/A
- ACRS 2015
- Fundamental
- Price
- SPCE $3.12
- ACRS $1.59
- Analyst Decision
- SPCE Hold
- ACRS Strong Buy
- Analyst Count
- SPCE 5
- ACRS 9
- Target Price
- SPCE $11.05
- ACRS $9.25
- AVG Volume (30 Days)
- SPCE 2.5M
- ACRS 1.3M
- Earning Date
- SPCE 08-06-2025
- ACRS 08-06-2025
- Dividend Yield
- SPCE N/A
- ACRS N/A
- EPS Growth
- SPCE N/A
- ACRS N/A
- EPS
- SPCE N/A
- ACRS N/A
- Revenue
- SPCE $5,512,000.00
- ACRS $17,777,000.00
- Revenue This Year
- SPCE N/A
- ACRS N/A
- Revenue Next Year
- SPCE $4,110.27
- ACRS $11.77
- P/E Ratio
- SPCE N/A
- ACRS N/A
- Revenue Growth
- SPCE N/A
- ACRS N/A
- 52 Week Low
- SPCE $2.18
- ACRS $1.05
- 52 Week High
- SPCE $8.32
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- SPCE 54.42
- ACRS 59.88
- Support Level
- SPCE $2.72
- ACRS $1.44
- Resistance Level
- SPCE $2.91
- ACRS $1.52
- Average True Range (ATR)
- SPCE 0.13
- ACRS 0.10
- MACD
- SPCE 0.03
- ACRS 0.00
- Stochastic Oscillator
- SPCE 94.57
- ACRS 79.17
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures advanced air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.